申请人在药物遗传学和药物基因组学领域进行了多年研究，已建立顺铂引起的耳毒性和儿童白血病易感性等遗传模型，找到了用于预防疾病和临床指导用药的遗传标签，为个体化治疗提供了基础。申请人已经发表SCI论文19篇（总影响因子199），以第一作者在Nature Genetics (IF=35.2)、JCO (IF=18)、JNCI (IF=14.3)、Cell Res (IF=10.5)、Blood (IF=9) 等杂志发表论文7篇 (总影响因子92)，其中在Nature Genetics、Cell Res、Blood等发表的文章系全部或部分在国内完成，这些研究受到国际重视，被他人在Nature等杂志中的报道引用近300次。本课题中，我们将以免疫抑制药物他克莫司引发的肾毒性为研究对象，结合全基因组测序和全基因组关联分析寻找直接影响他克莫司药物毒性的遗传变异，为临床指导用药提供了前提条件。

The applicant has been researching on pharmacogenetics and pharmacogenomics fields for more than 10 years, and identified the inherited predisposition to cisplatin induced ototoxicity and acute lymphoblastic leukemia susceptibility, respectively, which can thus be used to guide individualized therapy. Being the first author, our findings have been published as peer-reviewed papers in the top SCI journals, including Nature Genetics (IF=35.21)、Journal of Clinic Oncology (IF=18.04)、Journal of National Cancer Institute (IF=14.34), and etc, and was cited in papers (e.g., Nature) for around 300 times . Totally, I was listed as the first author in 7 papers (total IF = 92), while listed as co-author in 19 papers (total IF =199). Our next plan is to identify the genetic risk factors for Tacrolimus (FK506) induced nephrotoxicity, by integrating whole genome sequencing with genome wide association study, thus to guide the design for individualized treatments.